A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.
Seth Augenstein
Advertisement
Articles by Seth Augenstein
A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Study Shows Niraparib Extends Time Without Symptoms, Toxicity in Ovarian CancerPublished: September 21st 2019 | Updated:
Ovarian Suppression Combined with Tamoxifen May Help Premenopausal PatientsPublished: September 27th 2019 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
Families of Children With ALL Face Extreme Financial Toxicity
3
Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib
4
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
5
